The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Asian shares mostly declined Thursday as investors grappled with uncertainty ahead of the United States presidential election ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...

U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies overshadowed a jump for Google's parent ...

And in July, the FDA greenlit Lilly's Alzheimer's disease treatment, Kisunla. Sales have been limited but a recent approval in Japan could make it a significant growth driver in the quarters ahead.

Asian shares are mostly declining amid uncertainty ahead of the United States presidential election next week.

Eli Lilly reported weaker results for the latest quarter than analysts ... In stock markets abroad, indexes were mostly lower ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

U.S. stock indexes gave up an early gain and ended slightly lower following a mixed set of profit reports from giants like ...